Ratiopharm
Private Company
Funding information not available
Overview
Ratiopharm, founded in 1973 and headquartered in Ulm, Germany, has built a 50-year legacy as the country's premier provider of affordable generic medicines, encapsulated in its mission 'Gute Preise. Gute Besserung.' (Good Prices. Good Recovery.). Its strategic acquisition by Teva in 2010 transformed it into a central pillar of Teva's European operations, providing access to global R&D and a vast product portfolio. The company's strategy combines a broad portfolio of ~2,500 products with digital health tools and a strong sustainability focus to maintain market leadership and drive growth in the cost-conscious European generic drug sector.
Technology Platform
Specializes in pharmaceutical development and manufacturing technologies for bioequivalent generic drugs, including reverse-engineering, formulation science, and advanced serialization for supply chain security.
Opportunities
Risk Factors
Competitive Landscape
Ratiopharm competes in a crowded generics market against giants like STADA, Sandoz, and Viatris, as well as discount private labels. Its key advantages are unmatched brand trust in Germany and the global scale and R&D pipeline of its parent company, Teva.